Sign in →

Test Code CEASF Carcinoembryonic Antigen (CEA), Spinal Fluid

Reporting Name

Carcinoembryonic Ag (CEA), CSF

Useful For

Detecting meningeal carcinomatosis and intradural or extradural infiltration 

 

Differentiating brain parenchymal metastasis from adenocarcinoma or squamous-cell carcinoma

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

CSF


Specimen Required


Collection Container/Tube: Sterile vial

Submission Container/Tube: 13 x 75-mm tube

Specimen Volume: 0.5 mL


Specimen Minimum Volume

0.4 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
CSF Refrigerated (preferred) 14 days
  Frozen  90 days
  Ambient  7 days

Reference Values

<0.6 ng/mL

Tumor markers are not specific for malignancy, and values may vary by method.

Day(s) Performed

Monday through Saturday

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82378

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CEASF Carcinoembryonic Ag (CEA), CSF 2037-0

 

Result ID Test Result Name Result LOINC Value
CEASF Carcinoembryonic Ag (CEA), CSF 2037-0

Clinical Information

Carcinoembryonic antigen (CEA) normally is present in cerebrospinal fluid (CSF) in very low concentrations. Elevations in serum CEA can cause passive transfer to CSF. Tumors of the brain, especially metastatic tumors, can elevate CSF CEA.

Interpretation

Increased values are seen in approximately 60% of patients with meningeal carcinomatosis.

Cautions

Although the assay appears to be specific for adenocarcinoma and squamous cell carcinoma, increased carcinoembryonic antigen (CEA) values in cerebrospinal fluid (CSF) are not seen in all patients with such tumors of the brain.

 

Mildly elevated CEA values in CSF may be secondary to passive transfer from the serum in individuals with high serum CEA concentrations.

 

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results and the laboratory should be alerted if the result does not correlate with the clinical presentation.

Report Available

1 to 3 days

Reject Due To

No specimen should be rejected

Method Name

Immunoenzymatic Assay

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.